drugset / Trial / NCT07743931
Study on the Management of COMISA
Recruiting
150 enrolled
University Hospital, Grenoble
Centre Médical les Jasmins "Poumon et Sommeil" · collabHôpital Européen Marseille · collabHôpital de la Pitié Salpêtrière - AP-HP · collabPolyclinique Saint-Laurent - Hospitalité Saint-Thomas de Villeneuve · collab
NaSingle-groupOpen-labelTreatment
Summary
COMISA, the combination of obstructive sleep apnea (OSA) and insomnia, is a frequent and burdensome condition. Many patients with OSA experience clinically significant insomnia symptoms, and a substantial proportion of individuals with chronic insomnia also meet criteria for OSA. This comorbidity is associated with more severe symptoms, more complex diagnostic pathways, and reduced adherence to continuous positive airway pressure (CPAP) therapy. This study aims to better understand COMISA and evaluate whether adding daridorexant to CPAP treatment can improve treatment adherence and overall patient outcomes.
Timeline
- Start
- 2026-09-30
- Primary completion
- 2028-09
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daridorexant | Small molecule | 50 mg | — |